4DMedical Ltd (ASX: 4DX) Share Price and News

Mr Livingston was previously one of the founding partners of Lake Imaging, subsequently becoming part of Integral Diagnostics Ltd., where John was Chief Executive Officer and Managing Director. He has lectured in Australia and abroad on the digital radiology environment, as well as business strategies and systems within the commercial sector. John has commercial experience, having worked with the team at Lake Imaging and later Integral Diagnostics through acquisitions and the establishment of Greenfield facilities across Australia. During his career at Integral Diagnostics, John led the group through private equity investment with Advent Partners in 2014, and in 2015 John worked with Advent to list Integral Diagnostics on the ASX. John is a former Director of VicWest Community Telco, United Way and Ballarat Clarendon College (past Chairman); a current Director at Qscan (chair of the Risk and Audit committee), Comrad Medical Systems (Chairman), is an operating partner at Morrison in its health team.

Dr Figlin is the Steven Spielberg Family Chair in Hematology-Oncology, Professor of Medicine and Biomedical Sciences, Interim Director for Cedars-Sinai Cancer, and Interim Director of the Samuel Oschin Comprehensive Cancer Institute. He completed his residency and chief residency in internal medicine at Cedars-Sinai Medical Center and a fellowship in Hematology/Oncology at the David Geffen School of Medicine at the University of California, Los Angeles (UCLA). He is an Emeritus Professor of Medicine and Urology at the David Geffen School of Medicine at UCLA. Prior to joining Cedars-Sinai, Robert was the Arthur and Rosalie Kaplan Endowed Chair of the Department of Medical Oncology and Therapeutics Research, and the Associate Director for Clinical Research at the City of Hope Comprehensive Cancer Center. Prior to that, Robert served as the Henry Alvin and Carrie L. Meinhardt Endowed Chair in Urologic Oncology and Professor of Medicine and Urology in the Divisions of Hematology/Oncology and Urologic Oncology at the David Geffen School of Medicine at UCLA. Robert joined the UCLA faculty as Assistant Professor of Medicine in the Division of Hematology/Oncology and was Co-Director of the Jonsson Comprehensive Cancer Center's Oncology Program. He held the post of Medical Director of the Thoracic and Genitourinary Oncology Program in the Departments of Medicine, Surgery and Urology, and served as Program Director of Solid Tumor Developmental Therapeutics within the Cancer Center. Robert serves as the Emeritus Editor for Kidney Cancer Journal, and his studies have appeared in Clinical Cancer Research, Journal of Clinical Oncology, New England Journal of Medicine, The Lancet, JNCI, Lancet Oncology, and Journal of Urology, among others. He has authored over 425 peer reviewed articles, more than 70 book chapters, and has published as editor multiple books in kidney cancer. Robert's research focuses on renal cell carcinoma and thoracic malignancies. He established and directs the Kidney Cancer Program at Cedars-Sinai Medical Center, which aims to understand the biology of kidney cancer and translate that knowledge into novel treatment approaches. His leadership is in developing novel anticancer drugs that avoid the toxicity associated with standard treatments and furthers Cedars-Sinai's tradition of compassionate patient care. Robert is Chair of the Medical Advisory Committee.

Dr Fouras, before founding 4DMedical, was a Professor and Director of the Laboratory for Dynamic Imaging at Monash University, where his pioneering research in imaging fluid dynamics laid the foundation for XV Technology. He is published, with over 100 peer-reviewed papers. Dr Fouras's commitment to leadership extends beyond academia and medicine; he is a former Australian Army commissioned officer (Infantry) and recipient of the Australian Davos Connection's Australian Leadership Award (2013). He is an Honorary Professorial Fellow at the University of Melbourne. Today, Dr Fouras remains dedicated to expanding the global reach of 4DMedical's technologies, working with clinicians and healthcare partners worldwide to enable earlier, diagnosis, and better outcomes for patients living with lung disease.

Ms Bianchi is an experienced Non-Executive Director with a focus on companies operating in environments including health, finance and infrastructure. Her CEO and executive career brought commercial leadership and digital transformation to global listed corporates through to tech startups across U.S., Australia, India, Singapore, UK and Europe. She has an international technology research background including programs in health and telecommunications. Her product experience is in analytics, AI and SaaS where she took to market new products for diverse sectors including FinTech and Transport. Lil is a Non-Executive Director and member of the Innovation Committee for Qscan Radiology Group and Chair of Operational Risk and member of the Investment Committee for water infrastructure company Murrumbidgee Irrigation. Lil is chair of the Risk Committee.

Mr Sutton began his career as an actuarial analyst for Towers Perrin in Melbourne where he consulted to some of Australia's superannuation funds. He later worked for Towers Perrin in Brussels and London as an asset consultant before moving to Credit Suisse Asset Management and then Schroders Investment Management as a portfolio manager in their respective multi-manager teams. After twelve years in London, Julian returned to Australia and formed a sales and marketing business helping international fund management companies establish a presence in the Australian market. Julian is involved in Australia's start-up industry. He was an early investor in 4DMedical and is also an investor and non-executive Director at Perth-based biosensor company, VitalTrace. Julian is a member of the Risk Committee.

Dr McGinty is an experienced in health care strategy and imaging economics, and prominent advocate for patient-centered care. A Professor of Clinical Radiology and Population Health Sciences at Weill Cornell Medicine in New York City, she serves as Senior Associate Dean for Clinical Affairs. Geraldine has knowledge of reimbursement and effectively negotiates difficult strategic and contractual issues at the intersection of technology and healthcare. Between 2021 and 2023, Geraldine served on the Board of NextGen Healthcare (NASDAQ:NXGN), a company providing a range of software, services, and analytics solutions to medical and dental group practices. She was a member of the Compensation Committee. In 2021 Geraldine also joined the Governing Authority of her alma mater, the National University of Ireland, Galway, and is a member of the Audit and Risk Committee. From 2014-2021, Geraldine provided her experience to the Industrial Development Authority (IDA Ireland) as a Non-Executive Director. In this capacity she advised the Irish government on foreign direct investment policy, and chaired the Audit, Risk and Finance Committee. Geraldine is a member of the Medical Advisory Committee.

-

-

-